Ashwani Verma
Stock Analyst at UBS
(4.50)
# 1,022
Out of 4,407 analysts
203
Total ratings
57.9%
Success rate
14.7%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMRX Amneal Pharmaceuticals | Reiterated: Buy | n/a | $16.20 | - | 2 | Jun 11, 2026 | |
| INCY Incyte | Maintained: Hold | $94 → $103 | $108.53 | -5.10% | 11 | Jun 8, 2026 | |
| LEGN Legend Biotech | Rated: Buy | $31 → $49 | $35.87 | +36.60% | 8 | Jun 4, 2026 | |
| INSM Insmed | Reiterated: Buy | $166 | $97.85 | +69.65% | 7 | Jun 3, 2026 | |
| BHVN Biohaven | Reiterated: Hold | $11 | $11.28 | -2.48% | 6 | May 28, 2026 | |
| MPLT MapLight Therapeutics | Initiated Coverage: Buy | $48 | $27.75 | +72.97% | 1 | May 27, 2026 | |
| JAZZ Jazz Pharmaceuticals | Upgraded: Buy | $188 → $307 | $230.56 | +33.15% | 14 | May 19, 2026 | |
| CORT Corcept Therapeutics | Upgraded: Buy | $95 → $72 | $82.91 | -13.16% | 2 | May 13, 2026 | |
| ALKS Alkermes | Maintained: Buy | $42 → $48 | $44.28 | +8.40% | 7 | May 6, 2026 | |
| TEVA Teva Pharmaceutical Industries | Rated: Buy | $36 → $42 | $34.63 | +21.28% | 27 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $49 → $57 | $54.87 | +3.88% | 11 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $251 → $259 | $255.17 | +1.50% | 12 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $178 → $161 | $159.76 | +0.78% | 17 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $69 | $70.15 | -1.64% | 12 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $6 | $4.17 | +43.88% | 3 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $645 → $705 | $545.96 | +29.13% | 19 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $20 | $16.48 | +21.36% | 5 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $40 | $21.09 | +89.66% | 10 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,080 | $1,133.00 | -4.68% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $220 | $227.73 | -3.39% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $35 → $40 | $53.13 | -24.71% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $43 | $34.46 | +24.78% | 5 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $18 | $33.62 | -46.46% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.05 → $1.1 | $1.40 | -21.43% | 7 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $119 → $130 | $200.05 | -35.02% | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $2.75 | +81.82% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $0.7601 | n/a | 1 | Oct 11, 2022 |
Amneal Pharmaceuticals
Jun 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $16.20
Upside: -
Incyte
Jun 8, 2026
Maintained: Hold
Price Target: $94 → $103
Current: $108.53
Upside: -5.10%
Legend Biotech
Jun 4, 2026
Rated: Buy
Price Target: $31 → $49
Current: $35.87
Upside: +36.60%
Insmed
Jun 3, 2026
Reiterated: Buy
Price Target: $166
Current: $97.85
Upside: +69.65%
Biohaven
May 28, 2026
Reiterated: Hold
Price Target: $11
Current: $11.28
Upside: -2.48%
MapLight Therapeutics
May 27, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $27.75
Upside: +72.97%
Jazz Pharmaceuticals
May 19, 2026
Upgraded: Buy
Price Target: $188 → $307
Current: $230.56
Upside: +33.15%
Corcept Therapeutics
May 13, 2026
Upgraded: Buy
Price Target: $95 → $72
Current: $82.91
Upside: -13.16%
Alkermes
May 6, 2026
Maintained: Buy
Price Target: $42 → $48
Current: $44.28
Upside: +8.40%
Teva Pharmaceutical Industries
Apr 30, 2026
Rated: Buy
Price Target: $36 → $42
Current: $34.63
Upside: +21.28%
Apr 20, 2026
Maintained: Buy
Price Target: $49 → $57
Current: $54.87
Upside: +3.88%
Apr 10, 2026
Rated: Buy
Price Target: $251 → $259
Current: $255.17
Upside: +1.50%
Apr 6, 2026
Maintained: Buy
Price Target: $178 → $161
Current: $159.76
Upside: +0.78%
Mar 24, 2026
Maintained: Hold
Price Target: $69
Current: $70.15
Upside: -1.64%
Mar 24, 2026
Rated: Buy
Price Target: $10 → $6
Current: $4.17
Upside: +43.88%
Mar 5, 2026
Rated: Buy
Price Target: $645 → $705
Current: $545.96
Upside: +29.13%
Feb 27, 2026
Maintained: Buy
Price Target: $18 → $20
Current: $16.48
Upside: +21.36%
Jan 5, 2026
Maintained: Buy
Price Target: $35 → $40
Current: $21.09
Upside: +89.66%
Nov 7, 2025
Maintained: Buy
Price Target: $1,080
Current: $1,133.00
Upside: -4.68%
Nov 7, 2025
Maintained: Hold
Price Target: $220
Current: $227.73
Upside: -3.39%
Nov 6, 2025
Maintained: Hold
Price Target: $35 → $40
Current: $53.13
Upside: -24.71%
Oct 14, 2025
Maintained: Buy
Price Target: $50 → $43
Current: $34.46
Upside: +24.78%
Jul 29, 2025
Maintained: Hold
Price Target: $18
Current: $33.62
Upside: -46.46%
Jul 21, 2025
Maintained: Hold
Price Target: $1.05 → $1.1
Current: $1.40
Upside: -21.43%
Jul 14, 2025
Maintained: Hold
Price Target: $119 → $130
Current: $200.05
Upside: -35.02%
Jun 17, 2025
Maintained: Buy
Price Target: $5
Current: $2.75
Upside: +81.82%
Oct 11, 2022
Initiated Coverage: Buy
Price Target: $15
Current: $0.7601
Upside: n/a